Title: KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo
Authors: Duraffour, Sophie ×
Drillien, Robert
Haraguchi, Kazuhiro
Balzarini, Jan
Topalis, Dimitrios
van den Oord, Joost J
Andrei, Graciela
Snoeck, Robert #
Issue Date: Jan-2014
Publisher: American Society for Microbiology (ASM)
Series Title: Antimicrobial Agents and Chemotherapy vol:58 pages:27-37
Abstract: The availability of adequate treatments for poxvirus infections would be valuable not only for human, but also for veterinary use. In the search for novel antiviral agents, the 1' -methyl-substituted 4' -thiothymidine nucleoside, designated KAY-2-41, emerged as a potent inhibitor of poxviruses. In vitro, KAY-2-41 was active in the micromolar range against orthopoxviruses (OPVs) and against the parapoxvirus orf. The compound preserved its antiviral potency against OPVs resistant to the reference molecule cidofovir. KAY-2-41 had no noticeable toxicity on confluent monolayers, but a cytostatic effect was seen on growing cells. Genotyping of vaccinia (VACV), cowpox and camelpox viruses selected for resistance to KAY-2-41 revealed nucleotide deletion(s), close to the ATP binding site, or nucleotide substitution, close to the substrate binding site, in the viral thymidine kinase (TK, J2R) gene. These mutations resulted in low levels of resistance towards KAY-2-41, ranging from 2.7 to 6.0-fold, and cross-resistance to 5-bromo-deoxyuridine (5-BrdU) but not to cidofovir. The antiviral effect of KAY-2-41 relied, at least in part, on the activation (phosphorylation) by the viral TK as shown through enzymatic assays. The compound protected animals from disease and mortality after a lethal challenge with VACV, reduced viral loads in the serum and abolished virus replication in tissues. In conclusion, KAY-2-41 is a promising nucleoside analogue for the treatment of poxvirus-induced diseases. Our findings warrant the evaluation of additional 1' -carbon-substituted 4' -thiothymidine derivatives as broad spectrum antiviral agents, since this molecule also showed antiviral potency against herpes simplex virus type 1 in earlier studies.
ISSN: 0066-4804
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Virology and Chemotherapy (Rega Institute)
Translational Cell & Tissue Research
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
2014005.pdfOA article Published 1998KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science